Neuronetics, Inc. (NASDAQ:STIM) Stock Rockets 59% But Many Are Still Ignoring The Company
Neuronetics, Inc. (NASDAQ:STIM) Stock Rockets 59% But Many Are Still Ignoring The Company
The Neuronetics, Inc. (NASDAQ:STIM) share price has done very well over the last month, posting an excellent gain of 59%. But the last month did very little to improve the 65% share price decline over the last year.
Neuronetics, Inc.(纳斯达克股票代码:STIM)的股价在上个月表现良好,涨幅高达59%。但是,上个月几乎没有改善去年65%的股价下跌情况。
In spite of the firm bounce in price, Neuronetics' price-to-sales (or "P/S") ratio of 0.9x might still make it look like a strong buy right now compared to the wider Medical Equipment industry in the United States, where around half of the companies have P/S ratios above 3.1x and even P/S above 8x are quite common. However, the P/S might be quite low for a reason and it requires further investigation to determine if it's justified.
尽管价格大幅上涨,但与整个美国医疗设备行业相比,Neuronetics的0.9倍市盈率(或 “市盈率”)仍可能使其目前看起来像是一个强劲的买盘。在美国,大约有一半的公司的市盈率超过3.1倍,甚至市盈率也高于8倍也很常见。但是,市盈率很低可能是有原因的,需要进一步调查才能确定其是否合理。
Check out our latest analysis for Neuronetics
查看我们对神经元学的最新分析
![](https://newsfile.futunn.com/public/NN-PersistNewsContentImage/7781/20231218/0-a0112b9bddff0848aaa1959e2f0fa43b-0-732f580c5b41bcb55bcfe7a721e4e47c.png/big)
NasdaqGM:STIM Price to Sales Ratio vs Industry December 18th 2023
纳斯达克GMM:STIM 市销比率与行业对比 2023 年 12 月 18 日
How Neuronetics Has Been Performing
Neuronetics 的表现如何
Neuronetics certainly has been doing a good job lately as it's been growing revenue more than most other companies. Perhaps the market is expecting future revenue performance to dive, which has kept the P/S suppressed. If not, then existing shareholders have reason to be quite optimistic about the future direction of the share price.
Neuronetics最近确实做得很好,因为它的收入增长幅度超过了大多数其他公司。也许市场预计未来的收入表现将下滑,这抑制了市盈率。如果不是,那么现有股东就有理由对股价的未来走向持乐观态度。
If you'd like to see what analysts are forecasting going forward, you should check out our free report on Neuronetics.
如果你想了解分析师对未来的预测,你应该查看我们关于Neuronetics的免费报告。
What Are Revenue Growth Metrics Telling Us About The Low P/S?
关于低市盈率,收入增长指标告诉我们什么?
There's an inherent assumption that a company should far underperform the industry for P/S ratios like Neuronetics' to be considered reasonable.
人们固有的假设是,如果像Neuronetics这样的市盈率被认为是合理的,公司的表现应该远远低于该行业。
If we review the last year of revenue growth, the company posted a worthy increase of 12%. Pleasingly, revenue has also lifted 36% in aggregate from three years ago, partly thanks to the last 12 months of growth. So we can start by confirming that the company has done a great job of growing revenues over that time.
如果我们回顾一下去年的收入增长,该公司的收入增长了12%。令人高兴的是,收入也比三年前增长了36%,这在一定程度上要归功于过去12个月的增长。因此,我们可以首先确认该公司在这段时间内在增加收入方面做得很好。
Shifting to the future, estimates from the four analysts covering the company suggest revenue should grow by 14% each year over the next three years. With the industry only predicted to deliver 9.7% each year, the company is positioned for a stronger revenue result.
展望未来,报道该公司的四位分析师的估计表明,在未来三年中,收入每年将增长14%。预计该行业每年的收入仅为9.7%,因此该公司有望实现更强劲的收入业绩。
With this information, we find it odd that Neuronetics is trading at a P/S lower than the industry. Apparently some shareholders are doubtful of the forecasts and have been accepting significantly lower selling prices.
有了这些信息,我们觉得奇怪的是,Neuronetics的市盈率低于该行业。显然,一些股东对预测持怀疑态度,并一直在接受大幅降低的销售价格。
The Bottom Line On Neuronetics' P/S
Neuronetics P/S 的底线
Shares in Neuronetics have risen appreciably however, its P/S is still subdued. We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.
但是,Neuronetics的股价已大幅上涨,其市盈率仍处于低迷状态。我们可以说,市销比的力量主要不是作为估值工具,而是用来衡量当前的投资者情绪和未来预期。
To us, it seems Neuronetics currently trades on a significantly depressed P/S given its forecasted revenue growth is higher than the rest of its industry. There could be some major risk factors that are placing downward pressure on the P/S ratio. At least price risks look to be very low, but investors seem to think future revenues could see a lot of volatility.
在我们看来,鉴于Neuronetics的预测收入增长高于行业其他部门,其目前的市盈率似乎严重低迷。可能有一些主要的风险因素给市盈率带来下行压力。至少价格风险看起来很低,但投资者似乎认为未来的收入可能会出现很大的波动。
We don't want to rain on the parade too much, but we did also find 5 warning signs for Neuronetics (1 can't be ignored!) that you need to be mindful of.
我们不想在游行队伍中下太多雨,但我们也发现了 Neuronetics 的 5 个警告信号(1 个不容忽视!)你需要注意的。
If you're unsure about the strength of Neuronetics' business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.
如果您不确定Neuronetics的业务实力,为什么不浏览我们为您可能错过的其他公司提供的具有稳健业务基础的互动股票清单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接联系我们。或者,也可以发送电子邮件至编辑团队 (at) simplywallst.com。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。